Jiangsu Hengrui Medicine Co., Ltd. (SHA:600276)

China flag China · Delayed Price · Currency is CNY
51.51
+0.51 (1.00%)
May 7, 2025, 3:00 PM CST
9.22%
Market Cap 327.53B
Revenue (ttm) 29.19B
Net Income (ttm) 6.84B
Shares Out 6.36B
EPS (ttm) 1.09
PE Ratio 47.20
Forward PE 44.84
Dividend 0.20 (0.39%)
Ex-Dividend Date Jul 12, 2024
Volume 39,728,794
Average Volume 51,877,068
Open 52.10
Previous Close 51.00
Day's Range 51.01 - 52.25
52-Week Range 37.24 - 57.53
Beta 0.44
RSI 62.59
Earnings Date Aug 22, 2025

About Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes drugs in China and internationally. The company develops antineoplastic drugs; surgery medications; medicines for oncology, autoimmune diseases, pain management, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, hematological diseases, neurological diseases, and ophthalmology, etc.; analgesia and anesthesia products; and contrast agents. It is also involved in technical consulting; tra... [Read more]

Sector Healthcare
Founded 1970
Employees 20,238
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600276
Full Company Profile

Financial Performance

In 2024, Jiangsu Hengrui Medicine's revenue was 27.98 billion, an increase of 22.63% compared to the previous year's 22.82 billion. Earnings were 6.34 billion, an increase of 47.28%.

Financial Statements

News

There is no news available yet.